ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: In both wild-type and imatinib-resistant CML cell lines, DMP11 degraded the target protein BCR-ABL as well as SRC family proteins (Yes/Fyn/Fgr) in a time- and dose-dependent manner.